UBS Group
ABOS icon

UBS Group’s Acumen Pharmaceuticals ABOS Stock Holding History

UBS Group’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$87.7K Buy
37,146
+15,584
+72% +$39.8K ﹤0.01% 7059
2025
Q4 		$45.5K Sell
21,562
-9,279
-30% -$18.4K ﹤0.01% 7278
2025
Q3 		$52.7K Sell
30,841
-63,581
-67% -$88K ﹤0.01% 7526
2025
Q2 		$110K Sell
94,422
-28,593
-23% -$30.7K ﹤0.01% 7161
2025
Q1 		$135K Sell
123,015
-18,477
-13% -$26.4K ﹤0.01% 6810
2024
Q4 		$243K Buy
141,492
+118,741
+522% +$286K ﹤0.01% 6334
2024
Q3 		$56.4K Buy
22,751
+9,965
+78% +$27K ﹤0.01% 6735
2024
Q2 		$30.9K Buy
12,786
+6,143
+92% +$19.6K ﹤0.01% 7038
2024
Q1 		$26.9K Buy
6,643
+6,635
+82,938% +$25K ﹤0.01% 6780
2023
Q4 		$31 Sell
8
-92
-92% -$273 ﹤0.01% 9037
2023
Q3 		$415 Buy
+100
New +$618 ﹤0.01% 8511
2023
Q2 		– Sell
-3,137
Closed -$12.7K – 8819
2023
Q1 		$12.7K Buy
+3,137
New +$16.4K ﹤0.01% 7429
2022
Q4 		– Sell
-2,687
Closed -$27K – 10675
2022
Q3 		$27K Buy
+2,687
New +$15.4K ﹤0.01% 6980
2022
Q2 		– Sell
-5,245
Closed -$21K – 10229
2022
Q1 		$21K Buy
5,245
+4,388
+512% +$23.9K ﹤0.01% 7382
2021
Q4 		$6K Buy
857
+247
+40% +$2.71K ﹤0.01% 9245
2021
Q3 		$9K Buy
+610
New +$10.1K ﹤0.01% 8074

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

UBS Group's ABOS Position: Q1 2026 in Review

UBS Group increased its Acumen Pharmaceuticals (ABOS) stake by 72% in Q1 2026, buying an estimated $39.8K and bringing the position to 37,146 shares worth $87.7K. The position accounts for ﹤0.01% of the portfolio, ranked #7059.

UBS Group first reported a position in ABOS in Q3 2021 and has held it in 16 quarters since. The position peaked at $243K in Q4 2024. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • UBS Group held 37,146 shares of Acumen Pharmaceuticals worth $87.7K as of Q1 2026.
  • UBS Group bought 15,584 Acumen Pharmaceuticals shares in Q1 2026, an estimated $39.8K.
  • Acumen Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7059 holding.
  • UBS Group first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 16 quarters since.
  • UBS Group's Acumen Pharmaceuticals position peaked at $243K in Q4 2024.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.